“Research by independent consultant Boston Healthcare Associates modelling the budget impact of PromarkerD versus existing care standards says US public and private health insurers could save US$384 billion over a decade.”
“Management says some 31 million diabetics in America are at risk of developing DKD. PromarkerD uses a simple blood test to detect the early onset of DKD in patients with type 2 diabetes. Early and cost-effective prediction could reduce the need for expensive treatment at later stages of the disease such as dialysis and kidney transplants.“
Article: Vast US market opportunity seen for Proteomics kidney test
